Fast Track HTS: A Fast, Fixed Cost Route Through Hit Discovery

Launching in October 2024, Charles River is pleased to introduce a new approach for researchers conducting high-throughput screening studies. Fast-Track HTS, offered alongside our traditional tailored HTS cascade, allows researchers whose program meets Fast-Track criteria to take advantage of a pre-defined workflow, rapidly obtaining hit matter and early medicinal chemistry insight at a competitive fixed cost.

Through this standardized screening route, we are able to streamline the HTS cascade, enabling accelerated study speed and faster delivery of hits. This study type is particularly suitable for researchers with more limited funding or drug developers looking to quickly explore the tractability/druggability of a target to gain proof of concept ahead of funding applications.

Researchers will screen one of our premier compound collections to ensure the highest quality chemical starting point for the campaign. The Lead-Like Library is expertly curated and designed to maximize lead-like properties and diversity, with known problem chemotypes excluded.

Some of the key qualifying criteria for a Fast-Track HTS study include:

• A biochemical assay using one of our 1,536 compatible in-scope technologies
• Screening against the Charles River Lead-Like Library (~138 k compounds)
• In-scope validation via a single technology artefact or counter screen assay in the same format as primary

Researchers will ideally screen using their own protein, with all subsequent study consumables and assay reagents included within the scope of the project. Out-of-scope protein production can be added to a Fast-Track screening project where desired.

While Fast-Track HTS is designed to give you a head start towards the clinic by enabling faster acquisition of hit matter at a fixed price point, we understand that speed must be balanced with momentum, created by making tactical decisions based on meaningful data. Therefore, all Charles River high-throughput screening routes include full and open data and structure disclosure, and medicinal chemistry alignment, providing you with initial chemical-clustering and early SAR insight alongside your qualified XC50 curves, enabling you to move forward confidently with a greater weight of information to support your hit-to-lead choices.

Talk to one of our world-class scientists to learn more about the pre-defined assay criteria associated with a Fast-Track HTS study, screening costs, and in-scope technologies.

Talk to a screening expert

Public link

Please use the above public link if you want to share this noodl on another website.